National and Kapodistrian University of Athens
Ανοσοφαινοτυπική και κυτταρογενετική μελέτη της μονοκλωνικής Β λεμφοκυττάρωσης (ΜΒL)
Abstract
dc:descriptionMonoclonal B-cell Lymphocytosis (MBL) is the prelude of Chronic LymphocyticLeukemia (CLL) and probably other chronic lymphoproliferations. MBL ischaracterized by the presence of a monoclonal B cell expansion at small numbers inthe peripheral blood of an otherwise healthy individual. The diagnostic criteria forMBL were proposed by Marti et al in 2005 and are the following:– Absolute B cell count < 5000 cells/μL,– Light chain restriction ratio >3:1 or < 0.3:1,– Bone marrow infiltration <20% by monoclonal population– Normal physical examination (no organomegaly or lymphadenopathy or otherfeatures of a lymphoproliferative disorder,– No evidence of an underlying autoimmune/infectious disease,– Repeat assessment should demonstrate that the monoclonal B-cell expansion isstable over a 3-month period.Data from retrospective studies and screening studies of healthy people have revealedthat MBL is detected in a low frequency: 3-5% in general population, 5-8% for people>60 years old. Most MBL cases are asymptomatic, and thus the diagnosis usuallyoccurs randomly during routine hematological check-ups. Due to its low frequency, the biological and clinical features of MBL remain unexplored.Immunophenotypically, MBL may be classified into one of the followingcategories: a) CLL-like ΜΒL with a typical CLL phenotype (CD5+CD20dimCD23+),b) atypical ΜΒL (CD5+CD20bright and usually CD23+) and c) CD5neg MBL. Atypicaland CD5neg cases account for about 15-20% of all MBL όλων των MBL and theavailable information of these subsets is limited, as only a restricted number of suchcases have been recorded.The number of circulating B-cells holds also great importance in MBL and is usedto distinguish between two separate MBL entities: i) “low count MBL” with a medianclonal B-cell concentration of 1cell/μL and ii) “high count” with a median absolute Bcellcount of about 3000 cells/μl. Low count MBL are rarely found to progress toclinical MBL or to overt leukemia, whereas high count MBL has been estimated toprogress to CLL at a rate of approximately 1-2% per year.The present study included 171 high count MBL individuals with at least onemonoclonal B-cell population in their peripheral blood. We analyzed a sufficientnumber of cases in order to understand the biology of MBL and the mechanismsunderlying the progression from MBL to the clinical state of CLL or anotherlymphoproliferation. More specific, the following goals were set:i) Comparison of the three phenotypic categories according to haematological,biological, phenotypic and cytogenetic features.ii) Detection of changes that occur in the preclinical sate of MBL, regarding the Bcell kinetics and/or the presence of clonal evolution).iii) Estimate the risk of progression from MBL to overt disease according to theparameters found at the time of diagnosis or to the changes happen during thecourse of the disease.Our findings highlight that there is a high heterogeneity among MBL cases. Theheterogeneity is observed not only among the different MBL subsets but also withinthe same group, and refers mainly to clinical, immunophenotypic and cytogeneticfeatures. Each phenotypic subset showed a distinct panel of phenotypic profiles andcytogenetic aberrations. However, on the same time, many hematological andbiologic parameters were common among the three subsets. Moreover, thecomparison of MBL individuals with a number of patients from our archive (on thebasis of the same phenotypic profile) indicate that there are common biologic featuresshared among all MBL cases, which differentiate MBL from clinical disease Follow-up monitoring revealed two different patterns of B-cell kinetics: i) anincrease in apparently all blood counts and ii) an elevated B-cell count at the expenseof non B-cells, on the basis of stable total white blood cells and lymphocytes.Interestingly, both patterns resulted in the increase in the proportion of B-cellcomponent among the total lymphocyte count. The i-FISH reevaluation revealed thatclonal evolution is detected in all subsets of MBL, as a dynamic process, by which theB cell clone may acquire additional aberrations without necessarily a subsequentprogression to overt disease.To our knowledge this is the first study exploring clonal evolution in thepreclinical MBL. Most importantly, our results showed that MBL individuals withclonal evolution carried a higher risk of progression to CLL or other lymphoproliferative disorder. Moreover, the increased numbers of absolute B cellcount at diagnosis could predict a shorter time to progression to overt disease.Noteworthy, the B cell count at diagnosis was a risk factor for all three MBL subsets,suggesting that there may be common biologic pathways and mechanisms which leadto the progression to overt disease. In multivariable analysis both absolute B cellcount at diagnosis and the presence of clonal evolution, retained their independentprognostic value.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2015
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kostopoulos, Ioannis
- Κωστόπουλος, Ιωάννης
Subjects
dc:subject × 14- Μονοκλωνική Β λεμφοκυττάρωση
- Κλωνική εξέλιξη
- Μεσοφασικός φθορίζων in situ υβρισισμός
- Monoclonal B cell lymphocytosis
- Clonal evolution
- Flouorescent in situ hybridization
- Φυσικές Επιστήμες
- Βιολογία
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Natural Sciences
- Biological Sciences
- Medical and Health Sciences
- Health Sciences
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43083